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Idiopathic pulmonary fibrosis is a diffuse parenchymal lung disease of unknown cause. The natural history of
disease can vary considerably, making it difficult to predict the clinical trajectory for an individual patient. Accurate
prognostication is desirable for clinical management as well as for cohort enrichment in clinical trials of therapeutics.
Clinical and biomarker models of disease behavior have been developed to improve prognostication in idiopathic
pulmonary fibrosis, with moderate predictive capabilities. Integrated prediction models that combine both clinical
and biomarker variables will improve prognostication for patients and improved cohort enrichment strategies for
clinical trials. This goal may be best achieved through collaborative patient registries with prospectively collected
biological samples that allow for characterization of disease behavior in idiopathic pulmonary fibrosis.
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Idiopathic pulmonary fibrosis (IPF) is a diffuse parenchy-
mal lung disease of unknown etiology associated with a
median survival of 3 to 5 years after diagnosis [1]. Dis-
ease behavior is variable among patients, with some indi-
viduals remaining relatively stable over long periods,
while others may experience a slow progressive decline,
rapid decline, or suffer acute exacerbation [2]. Predicting
the clinical course in IPF is challenging due to the
heterogeneous nature of the disease, but it remains a
critically important goal for both clinical and research
purposes. Knowledge of an individual’s probability of
disease progression or risk of death may affect timing of
drug therapies or listing for lung transplantation. In clin-
ical trials of therapeutics, accurate prognostication is de-
sirable to maximize the likelihood of detecting treatment
effects through cohort enrichment. For these reasons,
several models of disease behavior for IPF have been
developed with the common goal of accurate prognosti-
cation. Each model has contributed valuably to our un-
derstanding of IPF, identifying key clinical, physiologic,
radiologic, pathologic, and biologic features associated
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Early risk prediction models incorporated baseline clin-
ical and radiographic parameters to predict mortality in
IPF. The composite clinical, radiological, and physio-
logical scoring system identified age, clubbing, smoking
history, lung volumes, end-exercise hypoxemia, and
chest radiographic evidence of pulmonary hypertension
and interstitial abnormalities to be associated with sur-
vival [3, 4]. The Composite Physiologic Index was simi-
larly developed, incorporating three lung function
parameters to predict mortality and accounting for the
confounding effects of concomitant emphysema in IPF
patients [5], a limitation of prior models.
More recently, du Bois et al. [6] developed a risk
scoring system based on age, history of respiratory
hospitalization, baseline forced vital capacity (FVC), and
change in FVC over 24 weeks to predict mortality. This
was subsequently modified to include a functional and
longitudinal parameter, the 6-minute walk distance
(6MWD) and change in this parameter over 24 weeks
[7]. Ley et al. [8] derived and validated the ‘gender, age,
physiology’ (GAP) model, which identified four readily
available baseline parameters, namely gender, age, FVC,
and diffusion capacity of the lung for carbon monoxide
(DLCO), to develop staging and risk prediction scores.
An alternative model in which the extent of fibrosis on
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The original du Bois and GAP models have subsequently
been combined to provide an integrated baseline and
longitudinal risk prediction approach [10].
These clinical models have demonstrated the impact
of cohort characteristics on calibration of risk. This is
most obvious in comparing risk in referral center-based
cohorts and clinical trial cohorts. Models derived in
center-based cohorts appear to significantly overestimate
mortality risk in clinical trial cohorts, where patients are
highly selected [11]. Additionally, age and gender appear
to be more relevant prognostic variables in clinical co-
horts, perhaps through capturing the influence of co-
morbidities, while adding relatively little in a clinical
trial cohort. Thus, calibration of risk prediction models
to the population of interest appears critical to accurate
quantification of risk.
Clinical risk prediction models provide important
prognostic tools for practice and clinical trial develop-
ment. However, their performance remains modest,
likely because clinical markers are limited in their inabil-
ity to directly assess the underlying pathobiology and
disease activity. Translational studies are providing novel
tools in the form of molecular and genetic biomarkers to
address this limitation.
Molecular and genetic biomarker-based models of
disease behavior
Several recent studies have identified molecular and gen-
etic biomarkers associated with clinical outcomes in IPF
[12]. These can be divided into three categories: genetic,
protein, and cellular.
Genetic-based biomarkers associated with worse sur-
vival in IPF include mucin 5B promoter polymorphisms
[13], shorter leucocyte telomere length [14], and the toll-
interacting protein single nucleotide polymorphism [15].
Protein-based biomarkers that have been associated with
worse outcomes in IPF include surfactant proteins A
(SP-A) [16] and D [17], Krebs von den Lungen-6 (KL-6)
[18, 19], CC-chemokine-ligand-18 [20], C-X-C motif
chemokine 13 [21, 22], matrix metalloproteinase (MMP)-3
[22] and MMP-7 [23], fibulin-1 [24], interleukin-8 and
intercellular cell adhesion molecule-1 [23], osteopontin
[25], periostin [26, 27], and collagen degradation products
[28]. Cellular biomarkers associated with worse outcomes
in IPF include regulatory T cells (Tregs) [29], semaphorin
7a + Tregs [30], and circulating fibrocytes [31].
Molecular and genetic biomarkers seem certain to add
to the predictive abilities of currently available clinical
risk prediction models. To date, few studies have exam-
ined this additive benefit and rigorous validation is lack-
ing, but superior model performance has been suggested
with certain combinations of clinical variables and bio-
markers [13, 18, 23, 32]. Song et al. [18] proposed thatthe combination of at least three biomarkers (e.g.,
MMP-7, SP-A, and KL-6) improved risk prediction over
clinical variables alone. Clearly, more needs to be done
to clarify the additive role of molecular and genetic
biomarkers.Conclusions
Taken together, these early reports highlight the poten-
tial for more accurate modeling of disease behavior in
IPF. However, several important limitations remain.
First, while survival is unquestionably a clinically mean-
ingful outcome, it is of less use to patients and clinicians
than pre-mortality outcomes such as disease progres-
sion. No model to date accurately predicts pre-mortality
outcomes such as loss of lung function or acute exacer-
bation. Second, available models demonstrate only mod-
est prediction accuracy. Potential explanations for this
include the inability to capture other co-morbidities
(e.g., cardiac disease, cancer) leading to death in IPF pa-
tients, the lack of reliable biomarkers of disease activity,
and the failure to account for processes such as acute
exacerbation. Lastly, quantification of risk may differ be-
tween patient populations, suggesting that models may
need to be tailored to the population of interest.
Future research will need to address these and other
limitations. We anticipate that models that combine
clinical and biological variables will lead to improved
prognostication for patients and improved cohort en-
richment strategies in clinical trials. To develop these
integrated models, we believe that a centralized registry
of well-characterized patients with systematically col-
lected bio-specimens will prove essential [33].
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